Issues
-
Cover Image
Cover Image
Diaphanous-related formins create new and/or stabilize microfilament and microtubule structures that support polarized cell adhesion, migration, and division. GTP-bound Rho proteins activate these formins by direct binding. The molecular mechanism of Rho activation is through steric disruption of intramolecular interactions between Dia-inhibitory (DID) and Dia-autoregulatory (DAD) domains. Screening for compounds that block DID-DAD binding led to the discovery of intramimics, which are small molecules that interfere with autoinhibition, resulting in activation of cellular formins. Using immunofluorescence to detect detyrosinated microtubules (a trait of stabilized microtubules), this image illustrates microtubules stabilized by intramimic exposure. For details on the mechanism and pharmacologic impairment of tumor growth, see article by Lash and colleagues on page 6793. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Breaking Advances
Reviews
Integrated Systems and Technologies
A DNA Methylation Prognostic Signature of Glioblastoma: Identification of NPTX2-PTEN-NF-κB Nexus
Microenvironment and Immunology
Enhancement of Antitumor Immunity in Lung Cancer by Targeting Myeloid-Derived Suppressor Cell Pathways
Molecular and Cellular Pathobiology
Hallmarks of Aromatase Inhibitor Drug Resistance Revealed by Epigenetic Profiling in Breast Cancer
The Transcription Factor IRF8 Counteracts BCR-ABL to Rescue Dendritic Cell Development in Chronic Myelogenous Leukemia
Intestinal GUCY2C Prevents TGF-β Secretion Coordinating Desmoplasia and Hyperproliferation in Colorectal Cancer
CD95L Cell Surface Cleavage Triggers a Prometastatic Signaling Pathway in Triple-Negative Breast Cancer
Therapeutics, Targets, and Chemical Biology
Personalizing the Treatment of Pediatric Medulloblastoma: Polo-like Kinase 1 as a Molecular Target in High-Risk Children
Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
Chk1 Targeting Reactivates PP2A Tumor Suppressor Activity in Cancer Cells
Cetuximab Response of Lung Cancer–Derived EGF Receptor Mutants Is Associated with Asymmetric Dimerization
Tumor and Stem Cell Biology
Retractions
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.